Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Biological: Tisagenlecleucel
Drug: lymphodepleting chemotherapy
Drug: Bridging Therapy

First Posted Date: 2018-08-01

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT03610724

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Johns Hopkins Oncology Center ORA, Baltimore, Maryland, United States
🇺🇸
Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States

and more 8 locations

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Asciminib

First Posted Date: 2018-07-30

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03605277

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)

First Posted Date: 2018-07-26

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03601442

Locations: 🇺🇸
Banner MDACC, Gilbert, Arizona, United States
🇺🇸
University of Arizona Cancer Center, Phoenix, Arizona, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 140 locations

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

Phase 3

Withdrawn

Conditions: Liver Transplantation

Interventions: Drug: TAC withdrawal
Drug: Everolimus with reduced TAC

First Posted Date: 2018-07-24

Last Posted Date: 2018-07-24

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03596970

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2

Recruiting

Conditions: FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Fludarabine
Drug: Cytarabine
Drug: Daunorubicin or idarubicin
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2018-07-19

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03591510

Locations: 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Miami Children s Hospital, Miami, Florida, United States
🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo 2 mL auto-injector
Drug: Placebo 1 mL prefilled syringe
Drug: Secukinumab 2 mL auto-injector
Drug: Secukinumab 1 mL prefilled syringe

First Posted Date: 2018-07-18

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT03589885

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: Omalizumab
Biological: Ligelizumab
Other: Placebo

First Posted Date: 2018-07-09

Last Posted Date: 2023-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1072

Registration Number: NCT03580369

Locations: 🇹🇷
Novartis Investigative Site, Samsun, Turkey

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: Ligelizumab
Biological: Omalizumab
Other: Placebo

First Posted Date: 2018-07-09

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1078

Registration Number: NCT03580356

Locations: 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸
Medical Resch of Arizona-Div of Allergy Asthma and Immunology, Scottsdale, Arizona, United States
🇺🇸
Atria Clinical Research Asthma and Allergy Institute, Little Rock, Arkansas, United States

and more 32 locations

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Phase 2

Completed

Conditions: CML
Leukemia, Myeloid Chronic
Hematologic Diseases
Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib add-on
Drug: Nilotinib
Drug: Imatinib

First Posted Date: 2018-07-06

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT03578367

Locations: 🇺🇸
Georgia Regents University, Augusta, Georgia, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: ianalumab

First Posted Date: 2018-07-02

Last Posted Date: 2024-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT03574545

Locations: 🇯🇴
Novartis Investigative Site, Amman, Jordan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy